NEW YORK (GenomeWeb) – NuMedii said today that it has struck collaborations with Yale School of Medicine and Brigham and Women's Hospital to use single-cell RNA sequencing to identify novel therapies and biomarkers for a chronic lung disease called idiopathic pulmonary fibrosis.
NuMedii — a Stanford University spinout developing artificial intelligence technology — will work with the laboratories of Naftali Kaminski at Yale and Ivan Rosas at Brigham and Women's, making use of a patient repository of single-cell RNA sequencing data and NuMedii's artificial intelligence technology for drug discovery to discover new biomarkers for IPF and new potential therapeutics.
Combining single-cell RNA sequencing data with NuMedii's AI technology will "provide unparalleled discovery capabilities to uncover novel mechanisms, cell types, targets, and biomarkers that we believe will be instrumental in identifying and developing precision therapies for orphan diseases like IPF," NuMedii CEO Gini Deshpande said in a statement.
"The data we will derive by molecularly profiling thousands of single cells in every patient's sample will allow us to understand disease at an unprecedented resolution, and should allow us to identify new cell types and biological mechanisms involved in IPF," Yale's Kaminski added.
Brigham and Women's Rosas also noted that his lab is "excited about the opportunity to leverage our combined scientific research along with data analytics and drug discovery capabilities to facilitate the translation of our research into new precision therapies that will help patients with IPF and the physicians who treat them."